ASX ANNOUNCEMENT

Lumos Diagnostics Receives Initial Orders for CoviDx™ In Canada

Melbourne, VIC. (20 December 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced it has received initial orders, worth approximately US$250,000, for its CoviDx™ SARS-CoV-2 rapid antigen test in Canada, after receiving authorisation to sell CoviDx™ in Canada in November. These orders are expected to ship in December 2021.

CoviDx™ is a rapid antigen POC test authorised for qualified healthcare providers for the detection of the SARS-CoV-2 virus. CoviDx™ received Interim Order authorisation from Health Canada in November 2021. Since then, Lumos has expanded its network of distributors for the Canadian market. The initial orders for CoviDx™, worth approximately US$250,000, were generated by multiple distributors as well as a direct order from a large-scale healthcare provider. Based on the strong demand for SARS-CoV-2 rapid antigen tests in Canada, Lumos expects to receive ongoing Canadian orders for CoviDx™ through FY 2022.

"Routine testing for SARS-CoV-2 using rapid antigen tests is a key element of Canada's strategy for managing the pandemic. In view of this, the Canadian Government has committed to a significant investment to ensure rapid SARS-CoV-2 tests are readily available for healthcare providers, schools, workplaces and individuals. We are pleased with these initial commercial orders for CoviDx™ so soon after receiving our Interim Order authorisation from Health Canada. Based on feedback from our Canadian distributors and healthcare organizations, we expect the demand and commercial momentum for CoviDx™ in Canada to continue to grow in 2022," **said Rob Sambursky, MD, President and Chief Executive Officer of Lumos Diagnostics.**

About the CoviDx™ Test

The CoviDx™ test gives qualified healthcare providers qualitative, easy-to-interpret results within 15-20 minutes in cases of suspected COVID-19 within the first five days of symptoms and when performing serial testing of asymptomatic patients.

The CoviDx™ test is a stand-alone point-of-care (POC) test that uses individual pre-filled extraction reagent vials to make it easy to administer – without any additional instruments or equipment. The test is compatible with both nasopharyngeal and the less invasive nasal swab sample collection and provides a

simple “yes/no” result. CoviDx™ SARS-CoV-2 Rapid Antigen Test is not intended for home testing, self-testing, or specimen self-collection.

This announcement was approved by the Lumos Diagnostics Disclosure Committee.

# # #

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information about Lumos Diagnostics and the CoviDx™ SARS-CoV-2 rapid antigen test, visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Jennifer Christiansen – Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153

Investor Contact:
Matthijs Smith
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598